IS6266A - Ísómerísk sambrædd pýrrólókarbazól og ísóindólón - Google Patents

Ísómerísk sambrædd pýrrólókarbazól og ísóindólón

Info

Publication number
IS6266A
IS6266A IS6266A IS6266A IS6266A IS 6266 A IS6266 A IS 6266A IS 6266 A IS6266 A IS 6266A IS 6266 A IS6266 A IS 6266A IS 6266 A IS6266 A IS 6266A
Authority
IS
Iceland
Prior art keywords
isoindolone
fused pyrrolocarbazole
isomeric fused
directed
same
Prior art date
Application number
IS6266A
Other languages
English (en)
Other versions
IS2186B (is
Inventor
L. Hudkins Robert
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Publication of IS6266A publication Critical patent/IS6266A/is
Publication of IS2186B publication Critical patent/IS2186B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pyrrole Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IS6266A 1999-08-20 2002-02-12 Ísómerísk sambrædd pýrrólókarbasól og ísóindólón IS2186B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15036799P 1999-08-20 1999-08-20
US09/640,825 US6399780B1 (en) 1999-08-20 2000-08-17 Isomeric fused pyrrolocarbazoles and isoindolones
PCT/US2000/022724 WO2001014380A1 (en) 1999-08-20 2000-08-18 Isomeric fused pyrrolocarbazoles and isoindolones

Publications (2)

Publication Number Publication Date
IS6266A true IS6266A (is) 2002-02-12
IS2186B IS2186B (is) 2006-12-15

Family

ID=26847579

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6266A IS2186B (is) 1999-08-20 2002-02-12 Ísómerísk sambrædd pýrrólókarbasól og ísóindólón

Country Status (26)

Country Link
US (4) US6399780B1 (is)
EP (1) EP1206473B1 (is)
JP (1) JP4776842B2 (is)
KR (1) KR100756686B1 (is)
CN (1) CN1370173A (is)
AT (1) ATE280172T1 (is)
AU (1) AU776475C (is)
BG (1) BG65545B1 (is)
BR (1) BR0013811A (is)
CA (1) CA2381885C (is)
CZ (1) CZ2002616A3 (is)
DE (1) DE60015153T2 (is)
EA (1) EA005920B1 (is)
ES (1) ES2230140T3 (is)
HK (1) HK1046904B (is)
HU (1) HUP0202758A3 (is)
IL (2) IL148180A0 (is)
IS (1) IS2186B (is)
MX (1) MXPA02001789A (is)
NO (1) NO323375B1 (is)
NZ (1) NZ517174A (is)
PL (1) PL354180A1 (is)
PT (1) PT1206473E (is)
SK (1) SK286805B6 (is)
TR (1) TR200200474T2 (is)
WO (1) WO2001014380A1 (is)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
AR035971A1 (es) 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
ES2307780T3 (es) * 2001-09-21 2008-12-01 Smithkline Beecham Corporation Compuestos quimicos.
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
WO2005000194A2 (en) * 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
DK1556083T3 (da) 2002-10-08 2011-04-04 Rinat Neuroscience Corp Fremgangsmåde til behandling af post-operative smerter ved indgivelse af en antistof mod nervevækstfaktor og sammensætning indeholdende samme
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
KR101410692B1 (ko) 2002-12-24 2014-06-24 리나트 뉴로사이언스 코프. 항-ｎｇｆ 항체 및 그것을 이용하는 방법
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
KR101637908B1 (ko) * 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
EP1804818A4 (en) * 2004-09-17 2009-07-22 Ford Henry Health System METHOD AND COMPOSITIONS FOR USE OF ANGIOGENESIS INHIBITORS FOR THE PREVENTION AND / OR CONTROL OF EPILEPSIA
PL2383268T3 (pl) 2005-02-04 2016-02-29 Astrazeneca Ab Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy
SI1853588T1 (sl) * 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
US7622482B2 (en) * 2005-02-16 2009-11-24 Astrazeneca Chemical compounds
NZ564317A (en) * 2005-05-16 2011-01-28 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
AU2006307657B2 (en) 2005-10-28 2010-10-28 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
CN101426774B (zh) 2006-04-19 2012-04-25 安斯泰来制药有限公司 唑类甲酰胺衍生物
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
EP2049535A1 (en) * 2006-08-02 2009-04-22 Takeda Pharmaceutical Company Limited Alpha-carboline derivatives and methods for preparation thereof
WO2008058402A1 (en) * 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
WO2010131855A2 (ko) 2009-05-13 2010-11-18 덕산하이메탈(주) 오원자 헤테로고리를 포함하는 화합물 및 이를 이용한 유기전기소자, 그 단말
CN101679429A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
ES2369596T3 (es) * 2007-05-04 2011-12-02 Astrazeneca Ab Derivados de amino-tiazolil-pirimidina y su uso para el tratamiento del cáncer.
DK2206707T3 (da) 2007-10-24 2014-08-11 Astellas Pharma Inc Azolcarboxamidforbindelse eller salt deraf
CA2711865A1 (en) 2008-01-11 2009-07-16 Astellas Pharma Inc. A pathological animal model simultaneously developing testicular pain or discomfort behaviors and urinary frequency
EP2288602A1 (en) * 2008-06-11 2011-03-02 AstraZeneca AB Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
BRPI0919488A2 (pt) * 2008-09-30 2015-12-01 Astrazeneca Ab composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
MX2011005055A (es) 2008-11-19 2011-05-31 Cephalon Inc Nuevas formas de un compuesto de indazolo [5,4-a]pirrolo[3,4-c]car bazol.
WO2010114267A2 (ko) 2009-03-30 2010-10-07 덕산하이메탈(주) 유기전기소자 및 그 화합물, 단말
ES2910305T3 (es) 2010-08-19 2022-05-12 Zoetis Belgium S A Anticuerpos anti-NGF y su uso
KR101497122B1 (ko) * 2011-08-09 2015-03-06 덕산네오룩스 주식회사 2개 이상의 오원자 헤테로고리를 포함하는 화합물 및 이를 이용한 유기전기소자, 그 단말
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
CN104364264B (zh) 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法
KR101478884B1 (ko) 2012-12-24 2015-01-05 충남대학교산학협력단 비스인돌일말레이미드계 화합물 및 이의 제조방법
WO2019101843A1 (en) 2017-11-23 2019-05-31 Biomed X Gmbh Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US4923986A (en) 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
FR2631199B1 (fr) 1988-05-09 1991-03-15 Centre Nat Rech Scient Reacteur a plasma
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
ES2118414T3 (es) 1993-05-28 1998-09-16 Cephalon Inc Utilizacion de derivados del indolocarbazol para el tratamiento de la prostata.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
DE69434294T2 (de) 1993-12-23 2005-12-29 Eli Lilly And Co., Indianapolis Proteinkinase c-inhibitoren
GB9416467D0 (en) * 1994-08-13 1994-10-05 Wellcome Found Compounds for use in medicine
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
ATE172199T1 (de) 1995-11-20 1998-10-15 Lilly Co Eli Proteinkinase-c-inhibitor
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
US5616724A (en) 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
JP2000516250A (ja) 1996-08-22 2000-12-05 ブリストルーマイヤーズ スクイブ カンパニー インドロピロロカルバゾールの細胞毒性アミノ糖および関連する糖誘導体
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones

Also Published As

Publication number Publication date
NO323375B1 (no) 2007-04-16
US7291732B2 (en) 2007-11-06
NO20020809D0 (no) 2002-02-19
BR0013811A (pt) 2002-07-23
AU776475C (en) 2005-04-07
NO20020809L (no) 2002-02-20
CZ2002616A3 (cs) 2003-04-16
US20020147341A1 (en) 2002-10-10
KR100756686B1 (ko) 2007-09-07
MXPA02001789A (es) 2003-07-14
JP4776842B2 (ja) 2011-09-21
IS2186B (is) 2006-12-15
AU6647100A (en) 2001-03-19
BG65545B1 (bg) 2008-11-28
DE60015153T2 (de) 2006-02-09
CA2381885A1 (en) 2001-03-01
IL148180A (en) 2008-04-13
PT1206473E (pt) 2005-01-31
SK2462002A3 (en) 2002-12-03
EP1206473B1 (en) 2004-10-20
CN1370173A (zh) 2002-09-18
BG106423A (en) 2002-09-30
EA200200271A1 (ru) 2002-08-29
WO2001014380A1 (en) 2001-03-01
US20030216419A1 (en) 2003-11-20
IL148180A0 (en) 2002-09-12
AU776475B2 (en) 2004-09-09
CA2381885C (en) 2009-10-27
HUP0202758A3 (en) 2004-12-28
KR20020038730A (ko) 2002-05-23
PL354180A1 (en) 2003-12-29
SK286805B6 (sk) 2009-05-07
HK1046904A1 (en) 2003-01-30
JP2003507480A (ja) 2003-02-25
EA005920B1 (ru) 2005-08-25
US20050107458A1 (en) 2005-05-19
DE60015153D1 (de) 2004-11-25
HK1046904B (en) 2005-05-06
US6399780B1 (en) 2002-06-04
NZ517174A (en) 2003-09-26
ATE280172T1 (de) 2004-11-15
ES2230140T3 (es) 2005-05-01
HUP0202758A2 (hu) 2002-12-28
US6635669B2 (en) 2003-10-21
TR200200474T2 (tr) 2002-06-21
US6872746B2 (en) 2005-03-29
EP1206473A1 (en) 2002-05-22

Similar Documents

Publication Publication Date Title
IS2186B (is) Ísómerísk sambrædd pýrrólókarbasól og ísóindólón
MXPA02004415A (es) Pirazolonas sustituidas con heterociclicas.
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
HUP0203567A2 (hu) APRIL-receptor (BCMA) és alkalmazásai
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
DE60107687D1 (de) Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden
FI964520L (fi) Atsabisykloyhdisteet
EA200100887A1 (ru) Циклические замещенные конденсированные пирролкарбазолы и изоиндолоны
DE69919700D1 (de) Überbrückte indenopyrrolocarbazole
EE05091B1 (et) Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
SG149045A1 (en) Novel fused pyrrolocarbazoles
TR200002380T2 (tr) Yeni triazolo (4,5-d) pirimidin bileşikleri
MY149041A (en) Novel fused pyrrolocarbazoles
YU62504A (sh) Triciklična 2-pirimidonska jedinjenja korisna kao inhibitori hiv reverzne transkriptoze
EE200200326A (et) Asendatud homopiperidüülbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
ES2195033T3 (es) Iso-indolonas condensadas utilizadas como inhibidores de proteina quinasa c.
EA199700223A1 (ru) Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции
EA200200981A1 (ru) Антагонисты рецептора il-8
ATE281455T1 (de) Oxindolderivate
ATE244714T1 (de) 1-(3-aminoindazol-5-yl)-3-phenylmethyl cyclische harnstoffe und ihre verwendung als hiv protease inhibitoren